Last reviewed · How we verify
Belantamab mafodotin lyophilized powder
Belantamab mafodotin lyophilized powder is a Monoclonal antibody-drug conjugate Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Multiple myeloma.
Monoclonal antibody targeting BCMA
Monoclonal antibody targeting BCMA Used for Multiple myeloma.
At a glance
| Generic name | Belantamab mafodotin lyophilized powder |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Monoclonal antibody-drug conjugate |
| Target | BCMA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Belantamab mafodotin is a monoclonal antibody-drug conjugate that targets B cell maturation antigen (BCMA) on the surface of multiple myeloma cells.
Approved indications
- Multiple myeloma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody (PHASE2)
- A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (PHASE1)
- A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (PHASE1)
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (PHASE1, PHASE2)
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma (PHASE1, PHASE2)
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Belantamab mafodotin lyophilized powder CI brief — competitive landscape report
- Belantamab mafodotin lyophilized powder updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Belantamab mafodotin lyophilized powder
What is Belantamab mafodotin lyophilized powder?
Belantamab mafodotin lyophilized powder is a Monoclonal antibody-drug conjugate drug developed by GlaxoSmithKline, indicated for Multiple myeloma.
How does Belantamab mafodotin lyophilized powder work?
Monoclonal antibody targeting BCMA
What is Belantamab mafodotin lyophilized powder used for?
Belantamab mafodotin lyophilized powder is indicated for Multiple myeloma.
Who makes Belantamab mafodotin lyophilized powder?
Belantamab mafodotin lyophilized powder is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What drug class is Belantamab mafodotin lyophilized powder in?
Belantamab mafodotin lyophilized powder belongs to the Monoclonal antibody-drug conjugate class. See all Monoclonal antibody-drug conjugate drugs at /class/monoclonal-antibody-drug-conjugate.
What development phase is Belantamab mafodotin lyophilized powder in?
Belantamab mafodotin lyophilized powder is in Phase 2.
What are the side effects of Belantamab mafodotin lyophilized powder?
Common side effects of Belantamab mafodotin lyophilized powder include Neutropenia, Thrombocytopenia, Anemia, Fatigue, Nausea.
What does Belantamab mafodotin lyophilized powder target?
Belantamab mafodotin lyophilized powder targets BCMA and is a Monoclonal antibody-drug conjugate.
Related
- Drug class: All Monoclonal antibody-drug conjugate drugs
- Target: All drugs targeting BCMA
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Multiple myeloma
- Compare: Belantamab mafodotin lyophilized powder vs similar drugs
- Pricing: Belantamab mafodotin lyophilized powder cost, discount & access